Coenen, Volker A.
Schlaepfer, Thomas E.
Meyer, Dora
Kilian, Hannah
Spanier, Susanne
Sajonz, Bastian E. A.
Reinacher, Peter C.
Reisert, Marco
Funding for this research was provided by:
Albert-Ludwigs-Universität Freiburg im Breisgau
Article History
Received: 24 February 2022
Accepted: 3 April 2022
First Online: 2 May 2022
Declarations
:
: The patient gave written informed consent. The study follows the Tenets of the Declaration of Helsinki.
: Related: <i>VAC and TES, as employees of the University of Freiburg, listed by the institution as inventors have filed a US provisional patent application generally related to highly focused DBS in the treatment of OCD (US Patent Application Number 63/253,740)</i> Unrelated: VAC receives a collaborative grant from BrainLab (Munich, Germany). He is a consultant for Ceregate (Hamburg, Germany), Cortec (Freiburg, Germany), and Inbrain (Barcelona, Spain). He has ongoing IITs with Boston Scientific (USA). Unrelated: TES has an ongoing IIT with Boston Scientific (USA). BEAS receives a research grant from Ceregate (Hamburg, Germany) unrelated to this publication. PCR receives research support from Else Kröner-Fresenius Foundation and Fraunhofer Foundation (ATTRACT). He has received personal honoraria for lectures or advice and is a consultant to Boston Scientific, Inomed, and Brainlab. MR, DM, HK, and SuS have nothing to declare.